BackAscendis Pharma A/S Overview
Ascendis Pharma A/S - ADR

Ascendis Pharma A/S Target Price

Where could ASND trade next? Consensus target price: $320.

Get informed when a big investor buys or sells

+ Follow

Share Price

$267.31

Average Target Price

$317.1018.6% upside

10 analysts in the last 4 months

High: $345 | Low: $275

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-27H.C. Wainwright$34529.1% upsideOpen
2026-08-18BMO Capital$31919.3% upsideOpen
2026-08-14RBC CapitalLuca Issi$2908.5% upsideOpen
2026-08-14Barclays$32923.1% upsideOpen
2026-08-13JefferiesKelly Shi$33324.6% upsideOpen
2026-07-23Morgan Stanley$2752.9% upsideOpen
2026-07-07RBC Capital$2804.7% upsideOpen
2026-05-15Evercore ISI$32923.1% upsideOpen
2026-05-11Barclays$34529.1% upsideOpen
2026-05-08Wells Fargo$32622% upsideOpen
2026-03-05Jefferies$2622% downsideOpen
2026-03-04Stifel NicolausAlex Thompson$33224.2% upsideOpen
2026-03-02Wolfe ResearchKalpit Patel$2602.7% downsideOpen
2026-03-02Cantor FitzgeraldLi Watsek$30012.2% upsideOpen
2026-03-02Evercore ISIJosh Schimmer$32421.2% upsideOpen
2026-03-02Goldman SachsPaul Choi$2554.6% downsideOpen
2026-02-12Wedbush$2732.1% upsideOpen
2026-02-12Oppenheimer$2622% downsideOpen
2026-02-12Stifel NicolausAlex Thompson$32521.6% upsideOpen
2026-02-12Morgan StanleyMaxwell Skor$2564.2% downsideOpen
2026-01-27BarclaysEliana Merle$34227.9% upsideOpen
2026-01-20RBC Capital$2506.5% downsideOpen
2026-01-20Wells FargoDerek Archila$33023.5% upsideOpen
2026-01-09Wells Fargo$32220.5% upsideOpen
2025-12-11Stifel NicolausAlex Thompson$2564.2% downsideOpen
2025-10-13Cantor FitzgeraldLi Watsek$2545% downsideOpen
2025-08-08RBC CapitalLuca Issi$23014% downsideOpen
2025-02-18Morgan Stanley$18032.7% downsideOpen
2024-09-23Bank of America SecuritiesTazeen Ahmad$19128.5% downsideOpen
2024-09-17Evercore ISIGavin Clark-Gartner$20523.3% downsideOpen
2024-09-17OppenheimerLeland Gershell$19028.9% downsideOpen
2024-09-17CitigroupDavid Lebowitz$20722.6% downsideOpen
2024-09-17Wells FargoDerek Archila$2898.1% upsideOpen
2024-09-16Bank of America SecuritiesTazeen Ahmad$17534.5% downsideOpen
2024-09-16Goldman SachsPaul Choi$20025.2% downsideOpen
2024-09-13CitigroupDavid Lebowitz$17833.4% downsideOpen
2024-09-05OppenheimerLeland Gershell$18032.7% downsideOpen
2024-08-13JefferiesKelly Shi$19626.7% downsideOpen
2024-05-30Stifel NicolausAlex Thompson$20025.2% downsideOpen
2024-05-15Morgan StanleyVikram Purohit$14047.6% downsideOpen
2024-03-14Evercore ISIJosh Schimmer$19128.5% downsideOpen
2023-01-03Wells Fargo$17733.8% downsideOpen
2022-11-15Morgan Stanley$14844.6% downsideOpen
2022-11-14Leerink Partners$14844.6% downsideOpen
2022-11-14Wedbush$16438.6% downsideOpen
2022-03-20Bank of America SecuritiesTazeen Ahmad$16139.8% downsideOpen
2022-02-28CitigroupDavid Lebovitz$18730% downsideOpen
2022-01-06Cowen & Co.Yaron Werber$13649.1% downsideOpen
2021-07-07Canaccord GenuityMichelle Gilson$19626.7% downsideOpen
2021-06-14Cantor FitzgeraldAlethia Young$20124.8% downsideOpen

Ascendis Pharma A/S (ASND) FAQ

The latest target price for ASND is $320. Investors often review this figure alongside Ascendis Pharma A/S's historical trend and sector peers before judging valuation or financial health.

Ascendis Pharma A/S trades near $267.31 while the consensus target sits at $320 (18.6% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting ASND's target price ($320), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Ascendis Pharma A/S's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.